Cancer Chemotherapy and Pharmacology

, Volume 18, Issue 1, pp 90–91 | Cite as

The effect of food on the oral administration of 6-mercaptopurine

  • Neil K. Burton
  • Michael J. Barnett
  • G. Wynne Aherne
  • Julienne Evans
  • Ian Douglas
  • T. Andrew Lister
Short Communication 6-Mercaptopurine

Summary

The effect of food on the bioavailability of 6-mercaptopurine (6-MP) has been investigated. Seven patients were studied on two separate occasions. On the first occasion 6-MP was administered p. o. after an overnight fast and on the second, 15 min after a standard breakfast. 6-MP concentrations were determined by high-performance liquid chromatography. Variable plasma drug levels were observed between individual subjects in the fasting state. The peak levels of 6-MP were lower and took longer to be achieved following administration after a standard breakfast than after an overnight fast. In two subjects levels were undetectable (<20 ng/ml). In view of these observations it is suggested that 6-MP should be administered before food if maximum blood levels are to be achieved.

References

  1. 1.
    Bosanquet AG, Gilby ED (1984) Comparison of the fed and fasting states on the absorption of melphalan in multiple myeloma. Cancer Chemother Pharmacol 12: 183Google Scholar
  2. 2.
    Burton NK, Aherne GW, Marks V (1984) A novel method for the quantitation of 6-mercaptopurine in human plasma using high performance liquid chromatography with fluorescence detection. J Chromatogr 309: 409Google Scholar
  3. 3.
    George CF (1984) Food, drugs and bioavailability. Br Med J 289: 1093Google Scholar
  4. 4.
    Lennard L, Rees CA, Lilleyman JS, Maddocks JL (1983) Childhood leukaemia: a relationship between intracellular mercaptopurine metabolites and neutropenia. Br J Clin Pharmacol 16: 359Google Scholar
  5. 5.
    Pearson ADJ, Craft AW, Eastham EJ, Aherne GW, Littleton P, Pearson GL, Campbell AN (1985) Small intestinal transit time affects methotrexate absorption in children with acute lymphoblastic leukemia. Cancer Chemother Pharmacol 14: 21Google Scholar
  6. 6.
    Schouten TJ, De Abreu RA, De Bruyn CHMM, Van der Kleijn E, Oosterbaan MJM, Schretlen EDAM, De Vaan GAM (1984) 6 mercaptopurine: pharmacokinetics in animals and preliminary results in children. Adv Exp Med Biol 165: 367Google Scholar
  7. 7.
    Zimm S, Collins JM, Riccardi R, O'Neill D, Narang PK, Chabner B, Poplack DG (1983) Variable bioavailability of oral mercaptopurine. Is maintenance chemotherapy in acute lymphoblastic leukemia being optimally delivered? N Engl J Med 308: 1005Google Scholar

Copyright information

© Springer-Verlag 1986

Authors and Affiliations

  • Neil K. Burton
    • 1
  • Michael J. Barnett
    • 2
  • G. Wynne Aherne
    • 1
  • Julienne Evans
    • 3
  • Ian Douglas
    • 4
  • T. Andrew Lister
    • 2
  1. 1.Division of Clinical BiochemistryUniversity of SurreyGuildfordEngland
  2. 2.ICRF Department of Medical OncologySt Bartholomew's HospitalLondonEngland
  3. 3.Medical CollegeSt Bartholomew's HospitalLondonEngland
  4. 4.St Luke's HospitalGuildfordEngland

Personalised recommendations